COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND APPLICATION METHODS Russian patent published in 2017 - IPC C07D239/70 A61K31/517 A61K31/58 A61P35/00 

FIELD: pharmacology.

SUBSTANCE: invention relates to a new combination of a) a formula Ia compound or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof in a therapeutically active amount. The combination can be used to treat prostate cancer. The invention also relates to a method for prostate cancer treatment using this combination. The formula Ia compound corresponds to the structural formula A combination is preferred where the formula Ia compound and abiraterone are at a ratio of 1:5 (mg/kg). It is desirable to use abiraterone acetate as a pharmaceutically acceptable salt of abiraterone. The combination is used when the cancer is associated with a PTEN mutation or with AKT overexpression or amplification with PI3K mutation, with Her2/ErbB2 mutation. It is preferable to use the combination if the cancer associated with the PTEN mutation is prostate cancer with zero PTEN status.

EFFECT: combination has increased activity and allows to significantly reduce the tumour volume in comparison with the control sample.

14 cl, 2 dwg, 2 tbl, 15 ex